📇 Rhumatologue · MANTES LA JOLIE · (78) · Libéral

M IBRAHIM EL-MEHEB

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
21 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
35 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
86.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 MANTES LA JOLIE (78)LibéralRPPS 10004011127

Expérience confirmée

35ans d'exercice (thèse 1991)

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Exulceratio simplex de dieulafoy : a propos d'un cas traite par sclerose endoscopique au polidocanol
1991
Médecine🎓 Reims
Paul Zeitoun

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression

Diabetes, obesity & metabolism · 2026

📚 1 citations

Lire l'abstract Crossref ↓

ABSTRACT Background Obesity is a complex chronic disease requiring effective long‐term management. We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. Methods We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss. Efficacy outcomes were percentage change in body weight, absolute change in body weight, fasting plasma glucose, HbA1c, and BMI. Lipid parameters included total cholesterol, LDL‐C, HDL‐C, VLDL‐C, and triglycerides. A random‐effects model was used to estimate mean differences (MD) or risk ratios (RR) with 95% CIs. Results Three RCTs ( n = 3545) were included. Cagrisema produced significantly greater percentage [MD −7.47% (95% CI: −10.58, −4.36); p < 0.001] and absolute [MD −7.60 kg (95% CI: −10.33, −4.86); p < 0.001] weight loss than semaglutide. Cagrilintide monotherapy weight loss was comparable to semaglutide. Lipids parameters were mostly similar between groups, though LDL‐C was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03]. Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administration‐site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]. Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide. Conclusion Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual‐agonist therapy for obese patients.

Cookies & analyse de trafic

M IBRAHIM EL-MEHEB

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (21) — classées par pathologie

Transversal6

Revue générale5

Génétique4

Revue / méta-analyse4

Épidémiologie & registres2

Essai clinique2

Pédiatrie2

Pharmacovigilance2

Gériatrie1

IA en rhumatologie1

Qualité de vie / PROMs1

Santé mentale / fatigue1

Partager cette fiche